

















































Cardiac failure (CF) is one leading cause of death [1], 
and its prevalence increases with age [1]. More than 
seven decades ago it was proposed that the failing  heart  
 
 
















































and its associated state, CF, might be caused by energy 
starvation [2]. Since then, a large set of published 
evidence has discussed the paramount importance of 
mitochondrial malfunction in the pathogenesis as well 






































In  this  study,  we  generated  mice  transgenically  over‐expressing  the  mitochondrial  protein  frataxin,  which  promotes
mitochondrial  energy  conversion  by  controlling  iron‐sulfur‐cluster  biogenesis  and  hereby  mitochondrial  electron  flux.
Hearts of transgenic mice displayed increased mitochondrial energy metabolism and induced stress defense mechanisms,
while overall oxidative stress was decreased. Following standardized exposure to doxorubicin to induce experimental
cardiomyopathy,  cardiac  function  and  survival  was  significantly  improved  in  the  transgenic  mice.  The  insulin/IGF‐1
signaling  cascade  is  an  important pathway  that  regulates  survival following  cytotoxic  stress  through  the downstream
targets protein kinase B, Akt, and glycogen synthase kinase 3. Activation of this cascade is markedly inhibited in the hearts
of  wild‐type  mice  following  induction  of  cardiomyopathy.  By  contrast,  transgenic  overexpression  of  frataxin  rescues
impaired insulin/IGF‐1 signaling and provides a mechanism to explain enhanced cardiac stress resistance in transgenic
mice. Taken together, these findings suggest that increased mitochondrial metabolism elicits an adaptive response due to
mildly  increased  oxidative  stress  as  a  consequence  of  increased  oxidative  energy  conversion,  previously  named
mitohormesis. This in turn activates protective mechanisms which counteract cardiotoxic stress and promote survival in
states  of  experimental  cardiomyopathy.  Thus,  induction  of  mitochondrial  metabolism  may  be  considered  part  of  a
generally protective mechanism to prevent cardiomyopathy and cardiac failure.  
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mitochondrial energy metabolism, which has not only 
been associated with CF but also to numerous other 
disorders, such as cancer, diabetes, obesity and general 
senescence. The mitochondrion hosts the enzymes of 
the Krebs cycle and the complexes of the electron 
transport chain (ETC) which generate ATP by oxidation 
of carbohydrates, fatty acids and amino acids. It 
therefore functions as the foremost supplier of energy 
substrate to maintain systemic energy balance and 
homeostasis.  
 
The protein frataxin acts as an important regulator of 
mitochondrial energy metabolism [11] which is highly 
expressed in metabolically active tissues such as brain, 
liver, skeletal and cardiac muscle [12]. It is a nuclear 
encoded protein which, after N-terminal signal peptide 
cleavage, is located within the mitochondrial matrix. 
Recent studies demonstrate that frataxin is an important 
regulator of iron metabolism and storage within the 
mitochondria, and a key factor of iron-sulphur-cluster 
(ISC) synthesis [13]. Friedreich’s Ataxia (FRDA), the 
most prevalent form of inherited neurodegenerative 
diseases, is caused by severely reduced expression of 
frataxin [14]. Primary symptoms are limb and gait 
ataxia, muscular atrophy and subsequent limb failure, 
carbohydrate intolerance, diabetes, and severe 
cardiomyopathy. Eventually, CF is fatal at an average 
age of 37 years [14]. A mouse model of frataxin-
deficiency in the heart demonstrates a similar phenotype 
with cardiac hypertrophy and early adult lethality [15]. 
These findings are supported by the notion that cardiac 
dysfunction is generally associated with impaired 
mitochondrial energy conversion and increased 
formation of ROS [5,16]. 
 
We now have generated a mouse model with transgenic 
over-expression of the mitochondrial protein frataxin to 
address our hypothesis that constitutive activation of 
mitochondrial energy metabolism might reduce the 
incidence of experimental CF. We employed 
doxorubicin (DOX), also used as an anticancer drug in 
human medicine, to induce experimental cardio-
myopathy. DOX is known to cause CF in humans once 
exceeding a cumulative dose threshold [17]. This in turn 
led to the use of DOX in a long-standing and 
standardized mouse model of cardiomyopathy, where a 
single injection of DOX primarily affects the 
myocardium and causes severe and potentially lethal CF 
[18,19]. We here show that transgenic activation of 
mitochondrial energy metabolism in the heart 





Generation of a mouse model with frataxin over-
expression 
 
For the purposes of this study we generated a transgenic 
mouse model over-expressing the mitochondrial protein 
frataxin. A cDNA encoding for human frataxin under 
the control of a ubiquitously active promoter was 
introduced into the murine genome to achieve a 
generally elevated expression of frataxin that, due to a 
hemagglutinin-tag, is distinguishable from expression of 
endogenous protein. We originally obtained 3 founder 
animals out of which only one was fertile and 
transmitted the transgene through the germ line. After 
confirmation of transgene presence in the genome by 
transgene-specific genomic PCR, we determined protein 
expression levels in various tissues (Figure 1A). 
Although a ubiquitously active promoter was used (see 
Methods), transgenic frataxin expression unexpectedly 
was restricted to a subset of tissues. Expression was 
found to be highest in heart, spleen, thymus and lung, 
where aside from the mature, processed 18 kD form of 
frataxin, a precursor of frataxin, sized 22 kD, could be 
detected through immunoblotting of the hemagglutinin-
tagged transgene (Figure 1A). While brain, skeletal 
muscle and kidney also expressed transgenic frataxin 
(Figure 1A), expression was barely detectable in others, 
such as liver and brown adipose tissue (Figure 1A). 
 
Frataxin over-expression promotes cardiac mito-
chondrial energy conversion 
 
We subsequently moved on to investigate possible 
phenotypic changes in the heart, as this tissue usually 
displays the most profound aberrations in FRDA 
patients [14]. To investigate whether over-expression of 
frataxin in an animal model leads to similar changes in 
energy metabolism as previously reported in in vitro 
models [11,20], we determined activity of aconitase 
(Figure 1B), a Krebs cycle enzyme that is known to 
depend on ISC and hence frataxin expression. 
Moreover, aconitase catalyzes the initial conversion 
step of citric acid to isocitric acid in the Krebs cycle and 
therefore represents an important step of mitochondrial 
substrate oxidation. Animals over-expressing frataxin 
showed a trend towards elevated levels of aconitase 
activity when compared to wild-type littermates (Figure 
1B) (P=0.0528). 
 
The levels of ATP, NADH, NADPH and reduced 
glutathione (GSH) in hearts of wild-type and transgenic 
littermate animals were quantified using high 
performance liquid chromatography (HPLC) (Figures 1C- 
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significantly increased in animals over-expressing 
frataxin (Figures 1C - E) indicating an increase in 
mitochondrial energy conversion and mitochondrial 
efficiency. We next hypothesized that an apparent 
induction of mitochondrial energy conversion might 
lead to an overall increase in oxidative damage. 
However, the concentration of GSH, which constitutes 
an important fuel to drive antioxidative protection of 
cellular structure, was found to be increased in animals 
over-expressing frataxin (Figure 1F). Similarly, 
thiobarbituric acid reactive substances (TBARS), which 
represent a measure of cellular lipid peroxidation, were 
significantly decreased in transgenic animals (Figure 









































Taken together, over-expression of frataxin promotes 
activity of ISC-dependent aconitase activity, elevates 
levels of metabolic intermediates of increased energy 
conversion, promotes glutathione-based ROS defense 
and, despite this increase in mitochondrial activity, 
decreases markers of oxidative stress. 
 
Activation of mitochondrial metabolism counteracts 
cardiomyopathy and reduces mortality 
 
As frataxin has been implicated in maintenance of 
cardiac function, we questioned whether frataxin over-
expression might in turn lead to improved performance 
of the heart under conditions of myocardial damage, 
namely an application of a single dose of DOX to 
induce CF.   
 
We investigated whether frataxin might contribute to 
improved function of the heart. Hemodynamic 
parameters of control and transgenic hearts was assayed 
to monitor cardiac performance of animals either left 
untreated or following DOX administration. In the basal 
state, no differences in any of the hemodynamic 
parameters could be observed when comparing wild-
type and transgenic animals that had not received DOX 
(Table 1). However, when animals were challenged 
with DOX prior to the measurements, transgenic 
animals displayed markedly improved cardiac 
performance. Left ventricular contraction during systole 
and the ventricular relaxation during diastole, end-
systolic and end-diastolic pressure (Pes and Ped) as well 
as maximum rate of left ventricular pressure rise 
(dP/dtmax) and fall (dP/dtmin) indicate contractility of 
the ventricle. Rates of ventricular pressure rise and 
decline were significantly improved in the hearts of 
transgenic animals (Figures 2A and B). A significant 
improvement was also observed in Pes and end-systolic 
volume (Ves) (Figures 2C and D). On the other hand, 
no changes could be detected in the equivalent end-
diastolic functions end-diastolic pressure (Ped) and end- 
diastolic volume (Ved) (Figures 2E and F). Tau (τ), the 
time constant of iso-volumetric left ventricular pressure 
decline was not changed significantly (Figure 2G). On 
the other hand, parameters of overall cardiac 
performance, i.e. stroke work, beat volume, cardiac 
output, ejection fraction and heart rate were all 
significantly increased in hearts with frataxin over-
expression following administration of DOX (Figures 
2H-L). Most importantly and in accordance with these 
findings, we observed a significantly decreased rate of 
mortality in frataxin over-expressing animals compared 
to wild-type littermates after DOX exposure (P=0.033) 
(Figure 3). 
Figure  1.  Over‐expression  of  frataxin  induces  mito‐
chondrial metabolism and ROS defense in the heart.  (A)
Representative anti‐hemagglutinin immunoblot showing several
tissues  from  a  transgene‐negative  littermate  (“‐“)  and  a
transgenic (“+”) animal each. “Control” is a previously published
cell  line  over‐expressing  frataxin  [20].  (B)  Aconitase  activity
measured in murine heart samples. Grey bars indicate wild‐type
(WT)  and  white  bars  indicate  frataxin‐transgenic  (FX)  animals
(also  applies  to  subsequent  figures).  (C)  ATP  ,  (D)  NADH,  (E)
NADPH,  (F)  reduced  glutathione  (GSH)  and  (G)  thiobarbituric
acid reactive substances (TBARS) contents in the hearts of wild‐



















































Over-expression of frataxin preserves insulin 
signaling in DOX-induced cardiomyopathy  
 
A close link exists between cardiac function and insulin 
signaling, as well as control of mitochondrial 
metabolism. We therefore quantified expression of 
components of the insulin signaling pathway in 
















































doxorubicin. Using immunoblotting, we analyzed 
expression and phosphorylation levels of IR and IGF-
1R, as well as their downstream targets Akt (protein 
kinase B), glycogen synthase kinase-3α/β (GSK-3α/β) 
and glycogen synthase (GS). Expression as well 
phosphorylation levels of these proteins remained 
unchanged in frataxin-transgenic animals as compared 




Untreated animals   Control   Transgenic   Significance  
Parameter   mean (±S.E.M)   mean (±S.E.M)   P-value  
Heart rate [1/min]   397 (±24)   395 (±26)   0.9439  
Pes [mmHg]   96.1 (±3.8)   99.9 (±4.9)   0.5488  
Ped [mmHg]   4.3 (±1.1)   6.1 (±1.6)   0.3603  
dP/dtmax [mmHg/min]   7254 (±780)   7399 (±1085)   0.9137  
dP/dtmin [mmHg/min]   -6078 (±593)   -5753 (±631)   0.7140  
Cardiac output [µl/min]   10015 (±753)   10510 (±1354)   0.7465  
Ejection fraction [%]   74.8 (±4.1)   70.2 (±4.4)   0.4621  
Stroke volume [µl]   25.9 (±2.5)   26.27 (±2.2)   0.9106  
Tau [ms]   11.9 (±0.8)   10.1 (±2.6)   0.5020  
Stroke work [µl*mmHg]   2470 (±228)   2683 (±350)   0.6133  
Ves [µl]   9.0 (±1.8)   12.0 (±2.0)   0.2878  
Ved [µl]   34.9 (±3.5)   38.2 (±3.8)   0.5184  
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lead to a marked reduction in phosphorylation levels of 
IR and IGF-1R (Figures 4A and B), as well as their 
downstream targets Akt and GSK-3α/β (Figures 4C to 
F). Phosphorylation of GSK-3α/β negatively regulates 
the activity of this kinase. Accordingly, phosphorylation 
of GS was found to be increased in wild-type animals 
exposed to DOX, which is known to inhibit the activity 
of this enzyme (Figure 4G). Meanwhile, under 
conditions of frataxin over-expression, we observed a 
reversal of the DOX-induced changes in wild-type 
animals. We here observed increased phosphorylation 
levels of the upstream insulin signaling components IR, 
IGF-1R and Akt (Figures 4A - E) as well as the 
downstream kinase GSK-3α/β (Figure 4F). According-
ly, phosphorylation of GS was reduced to levels 
observed in the untreated hearts (Figure 4G).  
 
Taken together, DOX-induced cardiomyopathy, cardiac 
function and survival was significantly improved in 
frataxin-transgenic mice compared to wild-type 
littermates. Activation of the insulin/IGF-1 signaling 
cascade is markedly inhibited in the hearts of wild-type 
mice following induction of cardiomyopathy. 
Importantly, transgenic overexpression of frataxin 
rescues the loss of insulin/IGF-1 signaling and provides 
a mechanism to explain enhanced cardiac stress 




We previously demonstrated that expression of 
frataxin correlates with mitochondrial energy 
metabolism in vitro and in vivo, affecting processes as 
diverse as longevity, diabetes, as well as growth and 
formation of cancer cells [11,20-23]. Therefore, we 
here have generated a transgenic mouse model with 
forced expression of frataxin. Frataxin-transgenic mice 
display increased mitochondrial energy metabolism in 
the heart, which – consistent with previously published 
in vitro data [24] - was accompanied by reduced 
oxidative stress. These observations indicate that over-
expression of frataxin in the heart improves 
mitochondrial energy conversion while it reduces the 
amount of ROS produced during electron transport. 
Following the injection of DOX to induce CF we 
observe significantly improved cardiac function and 
survival in mice transgenically expressing frataxin. 
Moreover, we here show that activation of 
mitochondrial metabolism is able to sustain activation 
of the Akt/PKB survival pathway through the 
insulin/IGF-1 receptor signaling axis under conditions 
of ROS-induced cardiomyopathy.  
  
Previous findings in cells, nematodes, knock-out mice 
and possibly humans demonstrate that frataxin 
expression tightly correlates with mitochondrial activity 
[11,20¬23,25,26] . Furthermore, we and others were 
able to show that increased formation of ROS can 
expedite health-promoting effects by inducing a 
hormetic response which in turn leads to improved 
stress resistance and/or ROS defense capacity (reviewed 
in [27]). In particular, this has been shown for frataxin-
overexpressing cells which, similarly to the transgenic 
mice studied in this manuscript, exhibit reduced ROS 
levels and increased GSH levels despite increased 
mitochondrial metabolism [24]. We therefore 
hypothesize that frataxin acts similar to physical 
exercise [28] through transiently increased ROS 
formation by subsequently promoting mitochondrial 

























It is well established that activation of insulin/IGF-1 
receptor signaling exerts cardioprotective action [29-
31]. Reduced insulin sensitivity and diabetes have been 
associated with increased incidence of CF [31] while 
cardiac muscle appears to respond to impaired insulin 
signaling by inducing mitochondrial biogenic response 
[32]. In the same line, treatment of rats with IGF-1 
protects from cardiomyopathy induced by DOX [33], 
and expression of IGF-1 and its receptor is increased in 
rat hearts following physical exercise [34,35]. Mice 
carrying a deletion of both IR and IGF-1R in the 
skeletal muscle and heart display a severe impairment 
of  cardiac function and die of heart  failure four  weeks  
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expression levels of genes of the ETC and especially 
mitochondrial fatty acid oxidation, not only suggesting 
that insulin signaling plays an essential role on heart 
physiology but also is an important regulator of 
mitochondrial energy metabolism [36].    
 
Activation of the Akt/PKB survival pathway has 
repeatedly been implicated in improved outcome 
following myocardial infarction. The anti-apoptotic 
function of Akt/PKB seems to be of particular 
importance to guarantee sustained heart contractility 
and function following reperfusion of the infarct region 
[37-39]. Conversely, over-expression of constitutively 
active Akt/PKB results in marked cardiac hypertrophy 
and other cardiac complications. Interestingly, and 
regardless of the negative growth characteristics, 
Akt/PKB-transgenic animals displayed significantly 
reduced infarct size following ischemia/reperfusion 
[40]. In accordance with our findings, it could be 
demonstrated earlier that DOX reduces Akt/PKB 
signaling [41,42]. Moreover, virus-mediated expression 
of AKT1 in mouse hearts ameliorated the effects of 
DOX-induced cardiomyopathy [43].  
 
Another interesting line of evidence links reduced 
activity of the downstream target of Akt/PKB, GSK-
3α/β, to cardioprotection. Following treatment with the 
polyphenolic compound resveratrol, GSK-3α/β is 
inhibited via phosphorylation [44]. Resveratrol protects 
the heart by a preconditioning mechanism acting though 
nitric oxide signaling [45], a process strikingly 
resembling the principle of hormesis. Resveratrol has 
been implicated in eliciting a hormetic effect in the 
process of ‘xenohormesis’ [46].   
 
In summary, we observe a consistent reduction of 
insulin/IGF-1 receptor signaling and reduced Akt/PKB 
phosphorylation, which has been previously reported 
following administration of DOX. The findings 
altogether indicate that over-expression of frataxin, due 
to its function as an activator of mitochondrial energy 
metabolism, rescues the DOX-induced down-regulation 
of insulinIGF-1 signaling. Moreover, we propose that 
mitochondrial metabolism, by primarily producing 
increased amounts of ROS, elicits a mitohormetic 
response which activates defense mechanisms in the 
heart. This effect may help to prevent cardiomyopathy 
and result in improved survival following treatment 
with DOX (Figure 5). Plausible future approaches for 
finding novel treatments of CF would therefore include 
the search for novel compounds that can enhance 
mitochondrial metabolism to induce such a 
mitohormetic response [4].   
 
MATERIALS AND METHODS 
 
Generation of frataxin-overexpressing animals. The 
cDNA encoding for the human frataxin protein was 
obtained and fused to a C-terminal hemagglutinin-tag as 
previously described [11]. The cDNA (deposited at 
AddGene for public access) was cloned into the NcoI 
and EcoRI restriction sites of the pDRIVE-CAG vector 
(InvivoGen, San Diego, CA, USA), which has been 
designed for ubiquitous expression in the mouse, hereby 
also replacing the original LacZ encoding sequence. 
The vector was then digested with the restriction 
enzymes SwaI and PstI to remove vector backbone and 
obtain the purified transgene construct for injection into 
the male pre-nucleus of fertilized murine oocytes 
derived from pure C57Bl/6 mice. All subsequent 
breedings were performed with C57Bl/6 wild-type 
animals to maintain a homogenous genetic background. 
Offspring was genotyped for integration of the 
transgene as described below. F1 offspring animals 
were genotyped to verify transmission through the germ 
line. One founder animal with stable and heritable 
expression of the transgene could be obtained, which was 
subsequently used to generate a mouse colony with stable 
over-expression of the frataxin protein. All animal 
experiments (generation of transgenes, maintenance and 
DOX experiments) were performed after approval by the 
corresponding institutional review boards. 
 
Animal maintenance. Animals were housed and 
maintained as described before [23]. For all experiments 
male animals at an age of 12-16 weeks were used.  
 
Genotyping. Breeding was designed to always yield 
heterozygous offspring by mating a heterozygous to a 
wild-type parental animal. Tail biopsies were obtained 
and DNA was extracted as described before [22]. PCR 
amplification was performed using forward and reverse 
primers located within the transgene with the sequences 
5’-GGCTATCTTCTCCATCCAGTG-3’ and 5’-
TCTTATCATGTCGAGCTAGCG-3’ for sense and 
antisense primers, respectively.  
  
Aconitase activity. Measurements were performed as 
described previously [22]. 
 
Quantification of metabolites. Metabolites were assayed 
as described [47]. In brief, tissue samples were removed 
and snap-frozen with liquid nitrogen. Sample was 
homogenized in chilled acetonitrile buffer to precipitate 
protein. Following the removal of protein for later 
quantification by chloroform-extraction, the metabolite-
containing fraction was subjected to HPLC separation 
and detection. Metabolites were identified by spiking of 
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was normalized to protein content.  
 
Thiobarbituric acid reactive substances (TBARS). 
Quantification was performed exactly as described 
previously [22].  
 
Doxorubicin-induced cardiomyopathy. Doxorubicin-
induced cardiomyopathy was induced by intraperitoneal 
injection of doxorubicin (Doxo Cell, Cell Pharm, 
Germany, 20 mg/kg) in 24 mice with transgenic 
overexpression of frataxin (FX) and in 24 wild-type 
littermates (WT). The investigation conformed to the 
Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH 
Publication No. 85-23, revised 1985).  
 
Surgical procedures and hemodynamic measurements.  
Left ventricular (LV) function was analyzed using 
pressure-volume loops. The animals were anesthetized 
(Thiopental 125 mg/kg i.p.), intubated, and artificially 
ventilated. As described recently [48], a 1.4 F micro-
conductance pressure catheter (Sciesence, Ontario, 
Canada) was positioned in the left ventricle for 
registration of LV pressure– volume (PV) loops in a 
closed-chest model. Indices of cardiac function were 
derived from PV data. Systolic function was quantified 
by LV end-systolic pressure (LVP, mmHg), dP /dt max 
(mmHg/s) and by ejection fraction (EF, %). Global 
cardiac function was quantified by the end systolic 
volume (ESV, µl), end diastolic volume (EDV, µl) 
stroke volume (SV, µl), cardiac output (CO, µl/min), 
and heart rate (HR, beat/min). Diastolic function was 
measured by LV end-diastolic pressure (LVEDP, 
mmHg), dP/dt min (mmHg/s), and the iso-volumetric 
relaxation time TAU (ms).  
 
Immunodetection. Detection of the various proteins by 
western blot was performed as described before [20]. 
Monoclonal antibodies were: hemagglutinin (clone 
12CA5) (Roche, Mannheim, Germany), basal insulin 
receptor beta, Tyr1135/1136 phosphorylated IGF-1 
receptor beta, and Tyr-1150/51 phosphorylated insulin 
receptor beta, basal glycogen synthase kinase 
alpha/beta, and Ser21/9 phosphorylated glycogen kinase 
alpha/beta (all from Cell Signaling Inc, Danvers, MA, 
USA). Polyclonal antibodies were: basal Akt, Ser308 
phosphorylated Akt, Ser473 phosphorylated Akt, basal 
glycogen synthase, Ser641 phosphorylated glycogen 
synthase (all from Cell Signaling Inc.) and alpha-tubulin 
(Sigma-Aldrich GmbH, München, Germany).  
 
Statistical analyses were performed using SPSS version 
13.0. Unpaired T-tests were used to compare transgenic 
animals and control littermates, except for survival rates 
where chi-square analysis was used. P-values below 
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